- Home
- MRVI vs DRTS Comparison
MRVI vs DRTS Comparison
Compare MRVI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- DRTS
- Stock Information
- Founded
- MRVI 2014
- DRTS 2015
- Country
- MRVI United States
- DRTS Israel
- Employees
- MRVI N/A
- DRTS N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- DRTS Medical/Dental Instruments
- Sector
- MRVI Health Care
- DRTS Health Care
- Exchange
- MRVI Nasdaq
- DRTS Nasdaq
- Market Cap
- MRVI 312.4M
- DRTS 262.6M
- IPO Year
- MRVI 2020
- DRTS N/A
- Fundamental
- Price
- MRVI $2.27
- DRTS $3.00
- Analyst Decision
- MRVI Hold
- DRTS Strong Buy
- Analyst Count
- MRVI 10
- DRTS 2
- Target Price
- MRVI $6.84
- DRTS $8.00
- AVG Volume (30 Days)
- MRVI 1.6M
- DRTS 39.8K
- Earning Date
- MRVI 08-06-2025
- DRTS 08-13-2025
- Dividend Yield
- MRVI N/A
- DRTS N/A
- EPS Growth
- MRVI N/A
- DRTS N/A
- EPS
- MRVI N/A
- DRTS N/A
- Revenue
- MRVI $241,856,000.00
- DRTS N/A
- Revenue This Year
- MRVI N/A
- DRTS N/A
- Revenue Next Year
- MRVI $10.62
- DRTS N/A
- P/E Ratio
- MRVI N/A
- DRTS N/A
- Revenue Growth
- MRVI N/A
- DRTS N/A
- 52 Week Low
- MRVI $1.67
- DRTS $1.75
- 52 Week High
- MRVI $10.03
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- MRVI 54.46
- DRTS 52.88
- Support Level
- MRVI $2.00
- DRTS $2.85
- Resistance Level
- MRVI $2.44
- DRTS $3.10
- Average True Range (ATR)
- MRVI 0.15
- DRTS 0.19
- MACD
- MRVI -0.00
- DRTS -0.02
- Stochastic Oscillator
- MRVI 61.36
- DRTS 37.33
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.